

This article was downloaded by: [Washington University in St Louis]

On: 08 October 2014, At: 15:21

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office:

Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

### First Total Synthesis of Cytotoxic Diarylheptanoids, Galeon, and Pterocarine

Qian Wang<sup>a</sup>, Jong-Keun Son<sup>a</sup> & Yurngdong Jahng<sup>a</sup>

<sup>a</sup> College of Pharmacy, Yeungnam University, Gyeongsan, Korea

Published online: 09 Mar 2007.

To cite this article: Qian Wang, Jong-Keun Son & Yurngdong Jahng (2007) First Total Synthesis of Cytotoxic Diarylheptanoids, Galeon, and Pterocarine, *Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry*, 37:5, 675-681, DOI: [10.1080/00397910601131015](https://doi.org/10.1080/00397910601131015)

To link to this article: <http://dx.doi.org/10.1080/00397910601131015>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## First Total Synthesis of Cytotoxic Diarylheptanoids, Galeon, and Pterocarine

Qian Wang, Jong-Keun Son, and Yurngdong Jahng  
College of Pharmacy, Yeungnam University, Gyeongsan, Korea

**Abstract:** The first total synthesis of cytotoxic diphenyl ether-type diarylheptanoids, galeon and pterocarine, was described in which the Ullmann reaction was employed at the final step for the diaryl ether formation of key intermediate, 1-(3-bromo-4-benzyloxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)heptan-3-one, assembled by a series of cross-aldol condensation from 3-methoxy-4-benzyloxybenzaldehyde.


**Keywords:** aldol, cytotoxicity, diarylheptanoid, galeon, pterocarine, Ullmann reaction

### INTRODUCTION

Diarylheptanoids are a class of natural products containing the 1,7-diphenylheptane skeleton and can be classified into three major groups: acyclics, cyclic biphenyls ([7.0]-metacyclophanes), and cyclic diphenyl ethers (14-oxa-[7.1]metaparacyclophanes).<sup>[1]</sup> Although linear diarylheptanoids and cyclic biphenylheptanoids have been studied extensively on account of their unique structures<sup>[2–5]</sup> and wide variety of biological properties,<sup>[6–19]</sup> studies on diphenyl ether-type cyclic diarylheptanoids such as acrogenins (**1a–d**),<sup>[20–26]</sup> galeon (**1e**),<sup>[27,28]</sup> and pterocarine (**1f**)<sup>[29]</sup> are mostly limited to their isolation from natural sources. Their intriguing structures have led to the establishment of a couple of strategic methods for the total synthesis of **1a–d** and their related acerosides.<sup>[30–32]</sup> However, there are no reported synthetic pathways for **1e** or **1f**. The methods reported previously from readily available compounds, however, are somewhat

Address correspondence to Yurngdong Jahng, College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Korea. E-mail: ydjahng@yumail.ac.kr

lengthy and are not suitable to apply to the synthesis of galeon and its related diarylheptanoids.



- 1a** X = CH<sub>2</sub>, Y = CH(OH), R = H (acerogenin A)  
**b** X = CH(OH), Y = CH<sub>2</sub>, R = H (acerogenin B)  
**c** X = CH<sub>2</sub>, Y = C=O, R = H (accrognin C)  
**d** X = C=O, Y = CH<sub>2</sub>, R = H (acerogenin L)  
**e** X = C=O, Y = CH<sub>2</sub>, R = OCH<sub>3</sub> (galeon)  
**f** X = C=O, Y = CH<sub>2</sub>, R = OH (pterocarine)

Recent findings on the potent cytotoxic activity of **1e** against selected cancer cell lines<sup>[33]</sup> and the inhibitory activity to the cell cycle at the G<sub>0</sub>/G<sub>1</sub> phase as well as the apoptosis inducing activity<sup>[29]</sup> of **1f** spurred us to devise a general and versatile synthetic method. This article described the first total synthesis of **1e** and **1f** from readily available starting materials.


## RESULTS AND DISCUSSION

The previous synthesis of acerogenin C and/or L employed two different methodologies. One<sup>[30,31]</sup> used the S<sub>N</sub>Ar reaction for ether formation and the acetoacetate ester synthesis for constructing diarylheptanoid skeleton, whereas the other<sup>[32]</sup> used the Ullmann reaction and the Wittig reaction, respectively. Novelty of the present strategy for synthesizing **1e** lies in the preparation of a suitably substituted 1,7-diphenylheptane derivative (**6**) by a series of cross-aldol condensation reactions and the formation of a diarylether bond at the late stage of synthesis via the Ullmann reaction.

The prerequisite 4-benzyloxy-3-methoxycinnamaldehyde (**2**) was prepared from commercially available 4-hydroxy-3-methoxybenzaldehyde in quantitative yield.<sup>[34,35]</sup> The cross-aldol condensation of **2** with acetone in the presence of 10% NaOH gave **3** in 93% yield, whereas such condensation of unprotected 4-hydroxy-3-methoxy-cinnamaldehyde led to much a lower yield. Catalytic hydrogenation of **3** under an H<sub>2</sub> atmosphere at room temperature for 24 h not only reduced the double bonds but also removed the protecting benzyl group to afford the corresponding **4** in quantitative yield, which was then subjected to a second aldol condensation reaction with 3-bromo-4-benzyloxybenzaldehyde to give the linear diphenylheptenoid **5** in 85% yield. The catalytic hydrogenation of **6** under an H<sub>2</sub> atmosphere for 2.5 h reduced only the double bond to afford the corresponding compound **6** as pale yellow oil in 81% yield. It should be noted that the benzyl moiety in compound **6** can be kept in protection by adjusting the reaction time.

Although several approaches to the formation of biaryl ethers have been introduced,<sup>[36]</sup> the Ullmann procedure is the best in some cases.<sup>[37]</sup> Thus the classical Ullmann condition i.e., using CuO/K<sub>2</sub>CO<sub>3</sub><sup>[38]</sup> as a catalyst was

applied to compound **6** to yield the corresponding cyclic diphenylheptanoid, 4-benzylgaleon (**7**), in 52% yield. The cyclic structure of **7** was confirmed by the characteristic high-field shift of the H-20 resonance in the  $^1\text{H}$  NMR spectrum due to the anisotropic effect of the neighboring orthogonal benzene ring ( $\delta\text{H}_{20} = 5.55$  in **7** vs.  $\delta\text{H}_{20} = 7.32$  in **6**). The selective cleavage of the benzyl ether by catalytic hydrogenation afforded the desired galeon (**1e**) in quantitative yield, of which the spectral ( $^1\text{H}$  and  $^{13}\text{C}$  NMR as well as distortionless enhancement by polarization transfer (DEPT), infrared (IR), and ultraviolet (UV) as well as the physical data were identical to those reported in the literature.



The *O*-demethylation of **1e** by a previously reported procedure<sup>[27]</sup> afforded perocarine (**1f**) in 88% yield. The physical and spectral data of the synthetic substances were identical to those of the natural products.

In conclusion, a simple and practical synthetic procedure for preparing diphenyl ether-type diarylheptanoid, galeon, was developed using the Ullmann diaryl ether formation of linear diarylheptanoid, which was prepared from readily available starting materials via a series of cross-aldol condensation reactions. Studies on resolving each enantiomer and applying this method to the synthesis of related diarylheptanoids, acerogenin C and L, are currently in progress.

## EXPERIMENTAL

Melting points were determined using a Fischer-Jones melting-point apparatus and are not corrected. IR spectra were obtained using a Perkin-Elmer 1330 spectrophotometer. NMR spectra were obtained using a Bruker-(250 spectrometer 250 MHz or 400 MHz for  $^1\text{H}$  NMR and 62.5 MHz or 100 MHz for  $^{13}\text{C}$  NMR) and are reported as parts per million (ppm) from the internal standard tetramethylsilane (TMS). Chemicals and solvents were commercial reagent grade and used without further purification. Electrospray ionization (ESI) mass spectrometry (MS) experiments were performed on a LCQ advantage-trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA). Elemental analyses were taken on a Hewlett-Packard Model 185B elemental analyzer.

All the spectral data of the compounds prepared are consistent with their structures.

**6:** Colorless oil (83%). IR (KBr)  $\nu$  3520, 1710  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 250 MHz)  $\delta$  7.57–7.30 (m, 6H), 7.00 (dd,  $J = 8.2$ , 2.0 Hz, 1H), 6.80 (d,  $J = 8.8$  Hz, 2H), 6.64 (s, 1H, H $2'$ ), 6.63 (dd,  $J = 8.5$ , 1.5 Hz, 1H), 5.48 (s, 1H, OH,  $\text{D}_2\text{O}$  exchangeable), 5.10 (s, 2H, Ph- $\text{CH}_2$ -), 3.85 (s, 3H,  $\text{OCH}_3$ ), 2.78 (t,  $J = 7.3$  Hz, 2H), 2.65 (t,  $J = 7.0$  Hz, 2H), 2.51 (t,  $J = 7.0$  Hz, 2H), 2.40 (t,  $J = 7.3$  Hz, 2H), 1.63–1.51 (m, 4H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 62.5 MHz)  $\delta$  209.78, 153.26, 146.25, 143.54, 136.54, 135.09, 134.05, 133.01, 128.49, 128.22, 127.83, 126.92, 120.77, 114.08, 113.83, 112.27, 110.85, 70.80, 55.78, 44.04, 42.79, 35.33, 31.16, 28.40, 23.27. MS (ESI) calcd. for  $\text{C}_{27}\text{H}_{29}\text{O}_4\text{Br}^+[\text{M} + \text{H}^+]$  498, found 498.

**7** (4-Benzylgaleon): Pale yellow needles (52%); mp 113°C. IR (KBr)  $\nu$  1714, 1518  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 250 MHz)  $\delta$  7.48 (overlapped d,  $J = 7.0$  Hz, 2H), 7.38–7.27 (m, 3H), 7.03 (d,  $J = 8.5$  Hz, 1H), 6.87–6.84 (m, 2H), 6.76 (d,  $J = 8.3$  Hz, 1H), 6.55 (dd,  $J = 8.0$ , 2.0 Hz, 1H), 5.55 (d,  $J = 1.9$  Hz, 1H), 5.38–5.18 (AB quartet, 2H), 3.72 (s, 3H), 2.97 (dd,  $J = 15.5$ , 8.2 Hz, 1H), 2.83 (dd,  $J = 13.0$ , 5.3 Hz, 1H), 2.71–2.58 (m, 2H), 2.41–2.20 (m, 2H), 2.02 (t,  $J = 11.6$  Hz, 1H), 2.03–1.75 (m, 1H), 1.69–1.50 (m, 4H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 62.5 MHz)  $\delta$  210.03, 152.28, 150.23, 145.32, 142.80, 139.67, 137.55, 134.67, 128.43, 127.67, 127.38, 124.25, 122.00, 121.10, 115.66, 115.25, 112.63, 71.68, 56.12, 46.10, 40.97, 36.01, 27.40, 27.03, 19.08. MS (ESI) calcd. for  $\text{C}_{27}\text{H}_{28}\text{O}_4^+[\text{M} + \text{H}^+]$  417, found 417.

**1e** (Galeon): White needles (99%); mp 178–180°C (lit.<sup>[27]</sup> mp 179–181°C, lit.<sup>[28]</sup> mp 178–180°C). IR (KBr)  $\nu$  3387, 1703, 1517  $\text{cm}^{-1}$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 250 MHz)  $\delta$  6.97 (d,  $J = 8.4$  Hz, H $_{18}$ ), 6.84 (d,  $J = 1.9$  Hz, H $_{16}$ ), 6.83 (d,  $J = 8.3$  Hz, H $_{19}$ ), 6.80 (d,  $J = 8.0$  Hz, H $_5$ ), 6.57 (d,  $J = 8.3$  Hz, H $_6$ ), 5.79 (s, OH,  $\text{D}_2\text{O}$  exchangeable), 5.53 (d,  $J = 1.9$  Hz, H $_{20}$ ), 3.69 (s, 3H,  $\text{OCH}_3$ ), 2.94 (dd,  $J = 16.2$ , 9.0 Hz, H $_{8A}$ ), 2.84–2.55 (m, 3H, 2H $_{14}$ , H $_{8B}$ ), 2.38–2.16 (m, 2H, H $_9$ ), 2.02–1.85 (m, 1H, H $_{11A}$ ), 1.76–1.71 (m, 1H,

H<sub>13A</sub>), 1.54–1.49 (m, 4H, H<sub>11B</sub>, 2H<sub>12</sub> & H<sub>13B</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.5 MHz) δ 210.29 (C=O), 152.07 (C17), 147.21 (C3), 143.04 (C4), 142.70 (C1), 140.03 (C15), 133.20 (C7), 123.95 (C18, CH), 121.94 (C19, CH), 121.86 (C6, CH), 115.00 (C5, CH), 114.91 (C16, CH), 112.18 (C20, CH), 56.00 (OCH<sub>3</sub>), 46.29 (C11, CH<sub>2</sub>), 41.25 (C9, CH<sub>2</sub>), 35.89 (C14, CH<sub>2</sub>), 27.33 (C13, CH<sub>2</sub>), 27.25 (C8, CH<sub>2</sub>), 18.98 (C12, CH<sub>2</sub>). MS (ESI) calcd. for C<sub>20</sub>H<sub>22</sub>O<sub>4</sub><sup>+</sup> [M+H<sup>+</sup>] 327, found 327.

**1f** (Pterocarine): White powder (88%), mp 175°C. IR (KBr)  $\nu$  3339, 1696, 1590, 1516 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz) δ 6.93 (d,  $J$  = 1.6 Hz, H<sub>16</sub>), 6.87 (d,  $J$  = 8.0 Hz, H<sub>18</sub>), 6.82 (d,  $J$  = 8.0, 1.2 Hz, H<sub>5</sub>), 6.77 (d,  $J$  = 8.0 Hz, H<sub>19</sub>), 6.62 (d,  $J$  = 8.0, 1.0 Hz, H<sub>6</sub>), 5.62 (br. s, 2H, C<sub>4</sub>-OH, C<sub>17</sub>-OH, D<sub>2</sub>O exchangeable), 5.54 (d,  $J$  = 1.0 Hz, H<sub>20</sub>), 2.86–2.82 (m, 2H, H<sub>8</sub>), 2.72–2.65 (m, 2H, 2H<sub>14</sub>), 2.38–2.16 (m, 2H, H<sub>9</sub>), 1.89–1.82 (m, 2H, 2H<sub>11</sub>), 1.67–1.63 (m, 2H, 2H<sub>13</sub>), 1.58–1.54 (m, 2H<sub>12</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 62.5 MHz) δ 210.48, 148.76, 146.72, 142.84, 140.63, 140.46, 133.97, 123.36, 122.94, 122.81, 117.81, 115.54, 112.51, 46.46, 41.07, 35.60, 27.26, 27.17, 18.95. MS (ESI) calcd. for C<sub>19</sub>H<sub>20</sub>O<sub>4</sub><sup>+</sup> [M+H<sup>+</sup>] 313, found 313.

#### ACKNOWLEDGMENT

Financial support from Korean Research Foundation Grant KRF-2006-005-J01101 is gratefully acknowledged. Dedicated to Professor See Ryun Chung in commemoration of his retirement from Yeungnam University.

#### REFERENCES

1. Keserü, G. M.; Nógrádi, M. The chemistry of natural diarylheptanoids. In *Studies in Natural Products Chemistry*; Atta-ur-Rahman, Ed.; Elsevier Science: New York, 1995, 17; pp. 357–394.
2. Semmelhack, M. F.; Helquist, P.; Jones, L. D.; Keller, L.; Mendelson, L.; Ryono, L. S.; Smith, J. G.; Stauffer, R. D. Reaction of aryl and vinyl halides with zerovalent nickel-preparative aspects and the synthesis of alnusone. *J. Am. Chem. Soc.* **1981**, *103*, 6460–6471, and references therein.
3. Whiting, D. A.; Wood, A. F. Cyclisation of 1,7-diarylheptanoids through oxidative, reductive, and photochemical radical processes: Total syntheses of the *m,m*-bridged biaryls myricanone and ( $\pm$ )-myricanol, and a related diaryl ether. *Tetrahedron Lett.* **1978**, 2335–2338.
4. Whiting, D. A.; Wood, A. F. Total syntheses of the meta, meta-bridged biphenyls ( $\pm$ )-myricanol and myricanone, and of an isomeric biphenyl ether, a 14-oxa[7,1]meta-paracyclophane. *J. Chem. Soc., Perkin Trans. 1* **1980**, 623–628.
5. Vermes, B.; Keserü, G.; Mezey-Vándor, G.; Nógrádi, M.; Tóth, G. The synthesis of garugambin-1. *Tetrahedron* **1993**, *49*, 4893–4900, and references therein.
6. Huang, M.-T.; Lysz, T.; Ferraro, T.; Abidi, T. F.; Laskin, J. D.; Conney, A. H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. *Cancer Res.* **1991**, *51*, 813–819.

7. Lee, S.-L.; Huang, W.-J.; Lin, W. W.; Lee, S.-S.; Chen, C.-H. Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. *Bioorg. Med. Chem.* **2005**, *13*, 6175–6181.
8. Weber, W. M.; Hunsaker, L. A.; Deck, L. M.; Vander Jagt, D. L. Synthesis of enone analogues of the natural product curcumin. Abstracts of Papers, 230th ACS National Meeting, American Chemical Society, Washington, DC, United States, Aug. 28–Sept. 1, 2005, MEDI-149.
9. Selvam, C.; Jachak, S. M.; Thilagavathi, R.; Chakraborti, A. K. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1793–1797.
10. Schraufstatter, E.; Bernt, H. Antibacterial action of curcumin and related compounds. *Nature (London)* **1949**, *164*, 456–457.
11. Jovanovic, S. V.; Steenken, S.; Boone, C. W.; Simic, G. H-atom transfer is a preferred antioxidant mechanism of curcumin. *J. Am. Chem. Soc.* **1999**, *121*, 9677–9681.
12. Barclay, L. R. C.; Vinqvist, M. R.; Kazuo Mukai, K.; Goto, H.; Hashimoto, Y.; Tokunaga, A.; Uno, H. On the antioxidant mechanism of curcumin: Classical methods are needed to determine antioxidant mechanism and activity. *Org. Lett.* **2000**, *2*, 2841–2843.
13. For curcumins: Huang, M.-T.; Smart, R. C.; Wong, C.-Q.; Conney, A. H. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid and ferulic acid on tumor promotion in mouse skin by 12-*O*-tetradecanoylphorbol-13-acetate. *Cancer Res.* **1988**, *48*, 5941–5946.
14. Liu, J.-Y.; Lin, S.-J.; Lin, J.-K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-*O*-tetradecanoylphorbol-13-acetate in NIH 3T3 cells. *Carcinogenesis* **1993**, *14*, 857–861.
15. Ruby, A. J.; Kuttan, G.; Babu, K. D.; Rajasekharan, K. N.; Kuttan, R. Anti-tumor and antioxidant activity of natural curcuminoids. *Cancer Lett.* **1995**, *94*, 79–83.
16. For biphenylheptaoids: Ishida, J.; Kozuka, M.; Wang, H.-K.; Konoshima, T.; Tokuda, H.; Okuda, M.; Yang Mou, X.; Nishino, H.; Sakurai, N.; Lee, K.-H.; Nagai, M. Antitumor-promoting effects of cyclic diarylheptanoids on Epstein–Barr virus activation and two-stage mouse skin carcinogenesis. *Cancer Lett.* **2000**, *159*, 135–140.
17. Ishida, J.; Kozuka, M.; Tokuda, H.; Nishino, H.; Nagumo, S.; Lee, K.-H.; Nagai, M. Chemopreventive potential of cyclic diarylheptanoids. *Bioorg. Med. Chem.* **2002**, *10*, 3361–3365.
18. Morikawa, T.; Tao, J.; Toguchida, I.; Matsuda, H.; Yoshikawa, M. Structure of new cyclic diarylheptanoids and inhibitors of nitric oxide production from Japanese folk medicine *Acer nikoense*. *J. Nat. Prod.* **2003**, *66*, 86–91.
19. Kang, H.-M.; Son, K.-H.; Yang, D. C.; Han, D.-C.; Kim, J. H.; Baek, N.-I.; Kwon, B.-M. Inhibitory activity of diarylheptanoids on farnesyl protein transferase. *Nat. Prod. Res.* **2004**, *18*, 295–299.
20. Nagai, M.; Kubo, M.; Fujita, M.; Inoue, T.; Matsuo, M. Acerogenin A, a novel cyclic diarylheptanoid. *Chem. Commun.* **1976**, 338–339.
21. Nagai, M.; Kubo, M.; Fujita, M.; Inoue, T.; Matsuo, M. Studies on the constituents of *Aceraceae* plants, II: Structure of aceroside I, a glucoside of a novel cyclic diarylheptanoid from *Acer nikoense* Maxim. *Chem. Pharm. Bull.* **1978**, *26*, 2805–2810.

22. Kubo, M.; Inoue, T.; Nagai, M. Studies on the constituents of aceraceae plants, III: Structure of acerogenin B from *Acer nikoense* Maxim. *Chem. Pharm. Bull.* **1980**, *28*, 1300–1303.
23. Kubo, M.; Nagai, M.; Inoue, T. Studies on the constituents of Aceraceae plants, IV: Carbon-13 nuclear magnetic resonance spectra of acerogenin A, rhododendrol, and related compounds, and structure of aceroside IV from *Acer nikoense*. *Chem. Pharm. Bull.* **1983**, *31*, 1917–1922.
24. Nagai, M.; Kubo, M.; Takahashi, K.; Fujita, M.; Inoue, T. Studies on the constituents of Aceraceae plants, V: Two diarylheptanoid glycosides and an arylbutanol apiosylglucoside from *Acer nikoense*. *Chem. Pharm. Bull.* **1983**, *31*, 1923–1928.
25. Nagai, M.; Kenmochi, N.; Fujita, M.; Furukawa, N.; Inoue, T. Studies on the constituents of Aceraceae plants, VI: Revised stereochemistry of (-)-centrolol, and new glycosides from *Acer nikoense*. *Chem. Pharm. Bull.* **1986**, *34*, 1056–1060.
26. Nagumo, S.; Kaji, N.; Inoue, T.; Nagai, M. Studies on the constituents of Aceraceae plants, XI: Two types of cyclic diarylheptanoid from *Acer nikoense*. *Chem. Pharm. Bull.* **1993**, *41*, 1255–1257.
27. Malterud, K. E.; Anthonsen, T.; Hjortas, J. 14-Oxa-[7.1]metaparacyclophanes from *Myrica gale* L., a new class of natural products. *Tetrahedron Lett.* **1976**, *35*, 3069–3070.
28. Morihara, M.; Sakurai, N.; Inoue, T.; Kawai, K.-I.; Nagai, M. Two novel diarylheptanoid glucosides from *Myrica gale* var. *tomentosa* and absolute structure of plane-chiral galeon. *Chem. Pharm. Bull.* **1997**, *45*, 820–823.
29. Liu, H. B.; Cui, C. B.; Cai, B.; Gu, Q. Q.; Zhang, D. Y.; Zhao, Q. C.; Guan, H. S. Pterocaraine, a new diarylheptanoid from *Pterocaria tonkinensis*, its cell cycle inhibition at G<sub>0</sub>/G<sub>1</sub> phase and induction of apoptosis in HCT-15 and K562 cells. *Chin. Chem. Lett.* **2005**, *16*, 215–218.
30. Isalas Gonzalez, G.; Zhu, J. First total synthesis of acerogenin C and aceroside IV. *J. Org. Chem.* **1997**, *62*, 7544–7545.
31. Isalas Gonzalez, G.; Zhu, J. A unified strategy toward the synthesis of acerogenin-type macrocycles: Total syntheses of acerogenin A, B, C, and L and aceroside IV. *J. Org. Chem.* **1999**, *64*, 914–924.
32. Keserü, G. M.; Nógródi, M.; Szöllösy, A. Synthesis of acerogenin C and (+)-acerogenin A, two macrocyclic diarylheptanoids constituents of *Acer nikoense*. *Eur. J. Org. Chem.* **1998**, 521–524.
33. Lee, K.-S.; Li, G.; Kim, S. H.; Lee, J.-S.; Woo, M.-H.; Lee, S.-H.; Jahng, Y.; Son, J. K. Cytotoxic diarylheptanoids from the roots of *Juglans mandshurica*. *J. Nat. Prod.* **2002**, *65*, 1707–1708.
34. Locksley, H. D.; Rainey, D. K.; Rohan, T. A. Bush pungent compounds, part I: An improved synthesis of the paradols (alkyl 4-hydroxy-3-methoxyphenethyl ketones) and an assessment of their pungency. *J. Chem. Soc., Perkin Trans. 1* **1972**, 3001–3006.
35. Itokawa, H.; Aiyama, R.; Ikuta, A. Synthesis of diarylheptanoids and assessment of their pungency. *Chem. Pharm. Bull.* **1983**, *31*, 2491–2496.
36. For a review based on the reaction mechanism, see Sawyer, J. S. Recent advances in diaryl ether synthesis. *Tetrahedron* **2000**, *56*, 5045–5065.
37. For a review for the classical Ullmann reaction condition, see Lindley, J. Copper assisted nucleophilic substitution of aryl halogen. *Tetrahedron* **1984**, *40*, 1433–1456.
38. Evans, D. A.; Ellman, J. A. The total syntheses of the isodityrosine-derived cyclic tripeptides OF4949-I11 and K-13: Determination of the absolute configuration of K-13. *J. Am. Chem. Soc.* **1989**, *111*, 1063–1072.